Company: SCLXW
Filing Date: 2025-08-04
Form Type: S-1
Source: 0001193125-25-172703
Chunk: 574

Company: Scilex Holding Co
Filing Date: 2025-08-04
Form: S-1
Chunk 574
---
---------|:----|:-------|-------:|
| 2025 (Remainder of 2025) |     | $      |  3,004 |
| 2026                     |     |        |  4,006 |
| 2027                     |     |        |  4,006 |
| 2028                     |     |        |  4,006 |
| 2029                     |     |        |  4,006 |
| Thereafter               |     |        | 12,423 |
| Total                    |     | $      | 31,451 |

7. Debt The Oramed Note On September 21, 2023, the Company entered into a securities purchase agreement with Oramed (the “Scilex-Oramed SPA”), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $ 101.9million, was to mature on March 21, 2025. It is payable in six principal installments, with the first installment of $ 5.0million payable on December 21, 2023, the second installment in the principal amount of $ 15.0million payable on March 21, 2024, the next three installments each in the principal amount of $ 20.0million payable on each of June 21, 2024, September 21, 2024and December 21, 2024and the last installment in the entire remaining principal balance of the Oramed Note payable on March 21, 2025. Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1) the greater of (x) 4% and (y) Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable in-kindon a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March 21, 2024, an exit fee of approximately $3.1 million has been earned with respect to the Oramed Note, which shall be due and payable on the date on which the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than